What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss Drugs
In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its shortage list. Here's what taking the drug of the list could mean for people taking tirzepatide or its compounded versions.
Why Ozempic, Zepbound, and other weight-loss drug dupes carry risks
Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for Now
Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the FDA revisits its decision to remove it.
Wegovy, other weight-loss drugs might help with alcoholism, opioid addiction
Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds.
Weight-Loss Meds Like Wegovy Could Battle Alcoholism
Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds. People taking this class of drugs, called glucagon-like peptide-1 receptor agonists (GLP-1),
Weight loss drugs could help with alcohol, opioid addiction, study says
Drugs​ like Mounjaro and Ozempic, which many use for weight loss,​​ may also help patients suffering from addiction, according to a new study.
Ozempic: Weight Loss Drug May Help With Addiction Too
These medications have been associated with a 40 percent reduction in opioid overdose and 50 percent lower rate of alcohol intoxication.
Weight loss drugs may help lower overdoses, alcoholism: Study
Researchers analyzed 1.3 million health records and found Ozempic, Mounjaro could lower rates of drug and alcohol overdoses.
Weight Loss Drugs Like Ozempic, Wegovy May Help Fight Alcoholism and Opioid Addiction
A new study reveals that glucagon-like peptide-1 receptor agonists (GLP-1), which include weight loss and diabetes meds Ozempic, Wegovy, Mounjaro or Zepbound, may help users overcome alcoholism and opioid addiction.
Eli Lilly (LLY): Revenue Boost from Zepbound and Mounjaro Amid Strong Market Projections
We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where Eli ...
ConsumerAffairs2d
Compounding pharmacies can keep making Mounjaro and Zepbound copies
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
FiercePharma12h
Lilly joins OAC campaign against obesity stigma, partnering on gallery of bias-free images for use in media coverage
Since 2021, the Obesity Action Coalition (OAC) has led a national public awareness campaign against weight bias with a goal ...
Trade group sues FDA over ending Mounjaro/Zepbound shortage
A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...
Eli Lilly's tirzepatide is off the FDA's shortage list: What it means for patients
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
Wegovy and Zepbound rival targeting ‘next generation' of obesity drugs, Zealand Pharma CEO says
Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...
BioPharma Dive4d
FDA, facing pressure, to review position on Zepbound, Mounjaro shortage
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...
The Times of Northwest Indiana2d
Get Healthy: Drugs can jump-start weight loss, giving healthy eating, exercise habits time to work
“ (Weight loss medications) can help, for sure, but exercise and getting enough protein to make sure you aren’t losing muscle ...
Eli Lilly Expects Zepbound Approval in Japan by Mid-2025, Eyes Weight-Loss Market
Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...
Eli Lilly’s Zepbound to undergo first-of-its-kind study on economic impact
Eli Lilly (NYSE:LLY) has partnered with the British government to launch a first-of-its-kind real-world study to evaluate the ...